Genmab

Genmab raises DKK 37.9 m through employee warrant exercise, boosting its oncology pipeline and reinforcing governance without diluting shareholders.

Genmab’s Q2 earnings beat sparks a surge in its stock and uplifts the Nordic markets, with analysts raising targets amid a strong oncology pipeline.

Genmab’s Q4 earnings hit a 5% revenue lift and raised analyst targets, sparking a 20% stock surge and boosting the Danish health‑care index.

Genmab tops 2026 first‑half forecasts, boosting revenue 25% with soaring DARZALEX and Kesimpta royalties, and raising full‑year guidance.

Genmab’s May 2026 capital increase sparks a sharp drop, yet analysts stay bullish—target prices around 2 200 DKK and buy ratings keep the stock attractive.

Genmab’s latest quarterly results reveal a resilient biotech firm on track to expand its antibody cancer therapies, showcasing solid growth and future potential.

Genmab’s 2025 stock outlook: strong market cap, bullish price target, and resilient biotech growth despite no new announcements.

Genmab A/S, a Danish biotechnology firm, continues to demonstrate momentum in the antibody-therapeutics market, driven by positive trial data and strategic growth initiatives, despite a recent dip in share price due to market volatility.